Compare PayPal Holdings, Inc. (PYPL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

PayPal (PYPL) trades at $55.02, up 0.75% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a P/E of 10.39 and net income margin of 14.36%, while recent earnings beat expectations in two of the last three quarters. Positive sentiment is fueled by a new partnership with Meta and ongoing cost-saving initiatives under CEO Enrique Lores.

The outlook is cautiously optimistic, with a consensus price target of $56.47 offering modest upside. Key opportunities include Venmo growth and AI integration, but risks involve competitive pressures in digital payments and slowing branded checkout growth. Wall Street sentiment is mixed, with 35.71% of analysts rating it a buy.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.